BioSpace News Archive

BUNAVAIL will be added to the formulary and covered in claims with an allowed condition for opioid use disorder, while Suboxone film, Suboxone tablet and generic equivalents, and Subutex tablet and its generic equivalents will be removed from the formulary.

There is currently no U.S. FDA approved drug for the treatment of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.

The current expected initial public offering price is between $14.00 and $16.00 per share.

This trial had two prospectively defined co-primary endpoints.

The results of the earlier study showed significant differences in favour of two higher doses of LMTX when taken as monotherapy compared with the intended 4 mg control dose taken as monotherapy or as add-on therapy to currently approved treatments for Alzheimer’s disease in pre-specified post hoc analyses.

CE marking allows for widespread commercialization of Aidoc’s solution in Europe.

Top-line results from the study are expected in 2018.

Centerview Partners LLC acted as financial advisor and Bryan Cave LLP acted as legal counsel to Express Scripts.

Brian McGee, Dr. James H. Anderson, Jr., MD, Dr. Craig Eagle, MD, and Dr. Gary H. Lyman, MD, MPH were elected as independent members of the Company’s Board of Directors.

Experienced and accomplished executive additions with proven track records in scaling manufacturing, process development, and CMC portfolio management.